News Pacira BioSciences, Inc.

Equities

PCRX

US6951271005

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 03:53:45 2025-07-15 pm EDT			5-day change	1st Jan Change
22.68 ^USD	-2.68%		-1.12%	+21.66%

Jul. 10	Pacira BioSciences announces workforce reduction	RE
Jun. 30	Pacira BioSciences, Inc.(NasdaqGS:PCRX) dropped from Russell 2000 Value-Defensive Index	CI

Pacira BioSciences announces workforce reduction	Jul. 10	RE
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Jul. 03	GL
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Jul. 03	AQ
Pacira BioSciences, Inc.(NasdaqGS:PCRX) dropped from Russell 2000 Value-Defensive Index	Jun. 30	CI
Pacira BioSciences, Inc.(NasdaqGS:PCRX) dropped from Russell 2000 Growth-Defensive Index	Jun. 30	CI
Pacira BioSciences, Inc.(NasdaqGS:PCRX) dropped from Russell 2000 Defensive Index	Jun. 30	CI
Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025	Jun. 18	GL
Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee	Jun. 11	CI
Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee	Jun. 11	GL
Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee	Jun. 11	AQ
Pacira Biosciences Insider Sold Shares Worth $377,226, According to a Recent SEC Filing	Jun. 05	MT
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Jun. 05	GL
Pacira Biosciences, Inc. Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee	May. 15	CI
Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee	May. 15	GL
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences	May. 14	GL
Lawsuit for Investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) announced by the Shareholders Foundation	May. 13	PR
Pacira Q1 Adjusted Earnings Unchanged; Revenue Rises; 2025 Sales Guidance Steady	May. 09	MT
Pacira BioSciences : PCRX 1Q25 Earnings Presentation FINAL	May. 08	PU
Pacira BioSciences, Inc., Q1 2025 Earnings Call, May 08, 2025	May. 08
Pacira: Q1 Earnings Snapshot	May. 08	AQ
Pacira BioSciences, Inc. announces an Equity Buyback for $300 million worth of its shares.	May. 08	CI
Tranche Update on Pacira BioSciences, Inc.'s Equity Buyback Plan announced on May 7, 2024.	May. 08	CI
Pacira BioSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 08	CI
Earnings Flash (PCRX) Pacira BioSciences Reports Q1 Adjusted EPS $0.62, vs. FactSet Est of $0.60	May. 08	MT
Earnings Flash (PCRX) Pacira BioSciences Posts Q1 Revenue $168.9M, vs. FactSet Est of $176.0M	May. 08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Pacira BioSciences, Inc.

Equities

PCRX

US6951271005

Pharmaceuticals

Filters